Regenacy Pharmaceuticals, Inc. — Form D
Regenacy Pharmaceuticals, Inc. of Waltham, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-04-08. The offering totals $40.7M, of which $20.9M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-04-08
- Form: D
- Accession: 0001807611-20-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $40.7M
- Amount sold: $20.9M
- Remaining: $19.9M
- Investors: 19
- Date of first sale: 2020-03-24
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-364531
Issuer
- Name: Regenacy Pharmaceuticals, Inc.
- CIK: 0001807611
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 303 Wyman Street, Suite 300, Waltham, MA, 02451
- Phone: 617-415-5030
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Marc Cohen | Director | Chicago, IL |
| Marc Cohen | Executive Officer | Chicago, IL |
| Simon Jones | Director | London, X0 |
| Simon Jones | Executive Officer | London, X0 |
| Daguang L Wang | Director | Waltham, MA |
| William L Chin | Director | Waltham, MA |
| Shixiang L Yan | Director | Waltham, MA |
| Michael L Huang | Director | Waltham, MA |
| John Rocha | Executive Officer | Waltham, MA |
Other filings by this issuer (1)
More